Personalis, Inc.

PSNL Healthcare Diagnostics & Research

Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS fell 30.4% and free cash flow fell 123.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

15.65 0.28 −1.76%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.5×
Dividend yield
—
F-score
4/9
Altman Z
3.35
Beneish M
−1.30
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
— — — 3 4 2 4 6 4
Altman Z-Score
— — 1.70 14.73 4.03 (1.39) (3.04) 0.45 3.35
P/S ratio
0.00 0.00 3.01 16.00 7.33 1.41 1.34 4.05 10.20
Altman Z″-Score (non-manufacturers)
— (16.47) 2.08 5.35 5.39 0.14 (5.75) (0.99) 0.31
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
— — (2.21) (0.99) (0.03) (3.01) (3.88) (3.56) (1.30)
P/Operating CF
1,334.41 1,334.41 81.63 (497.03) (41.00) (5.48) (7.32) (43.93) (31.93)
P/B ratio
0.00 0.00 1.84 6.46 2.02 0.42 0.76 1.69 2.72
Price to Tangible BV
0.00 0.00 1.84 6.46 2.02 0.42 0.76 1.69 2.72
EV/Sales
0.00 0.00 1.32 13.65 4.18 (0.89) 0.03 2.07 7.01
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.54 0.00 0.00 0.00
EV/Operating CF
12.12 12.12 (4.76) (25.16) (5.04) 0.82 (0.04) (3.89) (6.52)
EV/FCF
(21.53) (21.53) (3.25) (23.38) (4.36) 0.48 (0.03) (3.77) (6.15)
Quick Ratio
0.50 0.42 2.63 5.16 9.76 5.56 2.79 6.21 6.46
Current Ratio
0.53 0.51 2.79 5.43 10.16 6.03 3.11 6.52 6.76
Net Debt/EBITDA
1.08 1.84 7.24 5.65 5.01 1.57 1.13 3.08 2.93
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.25 1.81 0.66 0.39 0.27 0.19 0.28 0.34 0.23
Operating CF/Net income
(0.01) (0.28) 0.72 1.03 1.09 0.62 0.52 0.56 0.92
Capex/Depreciation
(4.24) (2.56) (1.78) (0.53) (1.38) (5.88) (1.17) (0.16) (0.74)
Interest Coverage
(17.01) (7.27) (19.79) (21,073.00) (355.18) (574.78) (999.42) (2,844.46) (429.55)
ROE
23.72% 19.99% (16,611.92%) (27.37%) (25.82%) (42.89%) (62.31%) (48.91%) (35.02%)
ROA
(62.73%) (95.45%) (25.21%) (20.53%) (20.34%) (32.88%) (41.83%) (32.82%) (26.89%)
ROIC
0.00% 0.00% 0.00% 0.00% (175.78%) (143.04%) (450.20%) (237.72%) (259.21%)
Return on Tangible Assets
143.35% 118.09% (24.18%) (21.51%) (21.28%) (49.59%) (69.03%) (36.92%) (29.75%)
Average Days of Receivables
75.27 43.07 18.47 29.47 78.85 93.38 88.07 35.11 84.91
Research and Development Expense of Revenue
105.60% 37.87% 34.38% 36.32% 57.68% 99.79% 88.15% 57.80% 72.17%
Selling, General and Administrative Expense of Revenue
105.41% 29.84% 33.86% 42.84% 55.79% 98.34% 67.67% 54.59% 76.92%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
8.02% 3.49% 7.45% 10.47% 16.82% 29.88% 19.12% 12.63% 13.54%
Graham Net Nets
0.34 0.34 0.45 0.14 0.37 1.36 0.52 0.40 0.27
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(4.91%) (4.91%) (28.98%) (3.25%) (10.37%) (123.38%) (110.29%) (23.70%) (11.43%)
Free Cash Flow Yield
(3.60%) (3.60%) (13.47%) (3.65%) (13.08%) (130.76%) (68.35%) (13.58%) (11.18%)
Revenue per Share
3.10 12.33 3.62 2.29 1.95 1.42 1.53 1.43 0.78
Operating CF per Share
0.10 1.82 (1.00) (1.24) (1.61) (1.54) (1.17) (0.76) (0.84)
Capex per Share
(1.70) (2.56) (0.47) (0.09) (0.25) (1.09) (0.23) (0.02) (0.05)
Free Cash Flow per Share
(1.61) (0.74) (1.47) (1.34) (1.87) (2.63) (1.39) (0.78) (0.89)
Cash per Share
7.46 6.45 7.12 5.91 6.54 3.67 2.37 3.12 2.69
Shareholders Equity per Share
0.00 (34.73) 5.92 5.67 7.07 4.77 2.69 3.43 2.93
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.00 (34.73) 5.92 5.67 7.07 4.77 2.69 3.43 2.93
Free Cash Flow
(4.87) (2.28) (26.45) (45.90) (81.91) (120.13) (67.17) (46.51) (79.45)
Working Capital
(22.80) (28.29) 89.62 180.08 286.92 166.57 99.51 171.89 228.32
Capital Expenditures
(5.16) (7.85) (8.38) (3.25) (11.08) (49.90) (10.91) (1.36) (4.50)
Net Current Asset Value
26.18 (118.50) 88.98 170.82 232.00 125.14 51.09 135.70 194.97
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.50 0.00 0.00 0.00
Capex to Sales
0.55 0.21 0.13 0.04 0.13 0.77 0.15 0.02 0.06
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.19 0.27 0.33 0.52 0.41 0.14 0.16 0.17 0.14
Cash ROIC
(21.52%) 2.63% (11.26%) (11.53%) (13.71%) (31.14%) (27.57%) (11.99%) (15.85%)
Accounts Receivable Turnover
2.94 11.82 16.81 16.30 6.89 3.71 4.28 6.54 5.72
Accounts Payable Turnover
2.21 4.90 6.20 7.49 6.15 4.68 3.98 5.42 5.56
Inventory Turnover
7.94 12.21 10.73 11.43 9.57 7.28 5.80 7.04 8.92
Average Days of Payables
125.49 92.27 62.10 51.76 62.52 90.75 98.53 40.40 88.01
Days of Inventory on Hand
25.56 48.24 38.98 35.16 38.03 60.66 69.17 37.51 41.63
Average Receivables
3.20 3.20 3.88 4.82 12.41 17.56 17.19 12.94 12.17
Average Payables
5.30 5.30 6.95 7.82 8.76 11.04 13.89 10.66 9.69
Average Inventory
1.48 2.13 4.02 5.12 5.62 7.10 9.53 8.21 6.04
Average Assets
37.62 20.84 99.48 201.07 320.69 344.61 258.90 247.68 302.22
Average Common Equity
(99.50) (99.50) 0.15 150.82 252.62 264.22 173.79 166.20 232.07

Fold the line items

Columns are period end dates